Anixa Biosciences Inc
Close on Oct 19, 2026
- Market cap
- $89.22M
- P/E (TTM)
- –
- Dividend yield
- –
About Anixa Biosciences
Pharmaceutical Preparations, SIC 2834
Anixa Biosciences, Inc. is a biotechnology company focused on developing therapies and vaccines to address critical unmet needs in oncology. The company's therapeutics portfolio includes liraltagene autoleucel, a chimeric endocrine receptor-T cell therapy targeting ovarian cancer that is being developed through its Certainty Therapeutics subsidiary in collaboration with the Moffitt Cancer Center. Its vaccine programs feature an investigational breast cancer vaccine targeting alpha-lactalbumin, developed alongside the Cleveland Clinic, as well as an ovarian cancer vaccine targeting the anti-Mullerian hormone receptor 2 protein extracellular domain. Anixa also conducts discovery work to identify vaccine targets for lung, colon, and prostate cancers.
The company operates from its principal executive offices located in San Jose, California. Clinical and pre-clinical development activities take place in the United States in partnership with research organizations including the Cleveland Clinic, Moffitt Cancer Center, and the National Cancer Institute. Outside its core oncology programs, Anixa maintains limited patent licensing activities from legacy operations.
Summary of the business section of Anixa Biosciences's latest annual report, written by StockData.
Company profile
Company
- Legal name
- Anixa Biosciences Inc
- Headquarters
- San Jose, CA
- Address
- 3150 Almaden Expressway, Suite 250 95118
- Phone
- (408) 708-9808
- Employees
- 4, Oct 31, 2025
- Industry
- Pharmaceutical Preparations
- Incorporated in
- Delaware
- Fiscal year ends
- October 31
- Auditor
- HASKELL & WHITE LLP, Irvine, California
Stock & identifiers
- Ticker
- ANIX
- Exchange
- Nasdaq
- Shares outstanding
- 35M, Sep 9, 2026
- Public float
- $85.12M, Apr 30, 2025
- Filer category
- Non-accelerated filer<br>Smaller reporting company
- Stock splits
- 1-for-25 reverse, Aug 18, 2015; 1-for-25 reverse, Jun 26, 2015; 2-for-1, Jun 18, 1996; 2-for-1, Mar 19, 1991; 5-for-4, Sep 16, 1987; 3-for-1, Nov 12, 1985
- SEC CIK
- 715446
- CUSIP
- 03528H109
- ISIN
- US03528H1095
- LEI
- 549300PW2C2QTAJL2D19
- EIN
- 11-2622630
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Amit Kumar | Chief Executive Officer, Director | 672,000 |
| Michael Catelani | President, COO, & CFO | 50,000 |
| Arnold M. Baskies | Director | 140,572 |
| Lewis H. Titterton jr | Director | 1,046,003 |
| Emily Gottschalk | Director | 45,665 |
CEO pay and shareholder return
Pay versus performance table from the proxy statement
| Fiscal year | CEO total pay | CEO pay actually paid | Other executives (avg) | Value of $100 invested | Peer group |
|---|---|---|---|---|---|
| FY2025 Dr. Kumar | $2.55M | $3.71M | $1.30M | $74 | $137 |
| FY2024 Dr. Kumar | $3.48M | $3.13M | $1.76M | $63 | $118 |
| FY2023 Dr. Kumar | $3.64M | -$2.62M | $1.97M | $56 | $81 |
| FY2022 Dr. Kumar | $2.16M | $4.77M | $1.85M | $117 | $66 |
“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.
Employees
Headcount reported in annual reports
“As of October 31, 2025, we had four full-time employees working for our Company and subsidiaries.”
Corporate history
Events identified from SEC filings